BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 9466665)

  • 1. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer.
    Ychou M; Pelegrin A; Faurous P; Robert B; Saccavini JC; Guerreau D; Rossi JF; Fabbro M; Buchegger F; Mach JP; Artus JC
    Int J Cancer; 1998 Feb; 75(4):615-9. PubMed ID: 9466665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.
    Ychou M; Azria D; Menkarios C; Faurous P; Quenet F; Saint-Aubert B; Rouanet P; Pèlegrin M; Bascoul-Mollevi C; Guerreau D; Saccavini JC; Mach JP; Artus JC; Pèlegrin A
    Clin Cancer Res; 2008 Jun; 14(11):3487-93. PubMed ID: 18519781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.
    Buchegger F; Pfister C; Fournier K; Prevel F; Schreyer M; Carrel S; Mach JP
    J Clin Invest; 1989 May; 83(5):1449-56. PubMed ID: 2708519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.
    Behr TM; Memtsoudis S; Sharkey RM; Blumenthal RD; Dunn RM; Gratz S; Wieland E; Nebendahl K; Schmidberger H; Goldenberg DM; Becker W
    Int J Cancer; 1998 Aug; 77(5):787-95. PubMed ID: 9688314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
    J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study.
    Buchegger F; Allal AS; Roth A; Papazyan JP; Dupertuis Y; Mirimanoff RO; Gillet M; Pelegrin A; Mach JP; Slosman DO
    Anticancer Res; 2000; 20(3B):1889-96. PubMed ID: 10928122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
    Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
    J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy.
    Buchegger F; Roth A; Allal A; Dupertuis YM; Slosman DO; Delaloye AB; Mach JP
    Ann N Y Acad Sci; 2000 Jun; 910():263-9; discussion 269-70. PubMed ID: 10911919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas.
    Sharkey RM; Goldenberg DM; Vagg R; Pawlyk D; Wong GY; Siegel JA; Murthy S; Levine GM; Izon D; Gascon P
    Cancer; 1994 Feb; 73(3 Suppl):864-77. PubMed ID: 8306272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor scintigraphy with 131I anti CEA monoclonal antibodies and F(ab')2 in colorectal cancer.
    Henze E; Kübel R; Waitzinger J; Büchler M; Adam WE; Beger HG
    Eur J Nucl Med; 1987; 13(3):125-9. PubMed ID: 3622555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.
    Juweid ME; Sharkey RM; Behr T; Swayne LC; Dunn R; Siegel J; Goldenberg DM
    J Nucl Med; 1996 Sep; 37(9):1504-10. PubMed ID: 8790202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
    Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
    Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of therapeutic efficacy and host toxicity of two different 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model.
    Blumenthal RD; Sharkey RM; Kashi R; Goldenberg DM
    Int J Cancer; 1989 Aug; 44(2):292-300. PubMed ID: 2759735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carcinoembryonic antigen antibodies.
    Delaloye B; Bischof-Delaloye A; Buchegger F; von Fliedner V; Grob JP; Volant JC; Pettavel J; Mach JP
    J Clin Invest; 1986 Jan; 77(1):301-11. PubMed ID: 3484753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
    Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Hanley D; Herskovic T; Markowitz A; Siegel J; Goldenberg DM
    Cancer Res; 1995 Dec; 55(23 Suppl):5946s-5951s. PubMed ID: 7493375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients.
    Murray JL; Rosenblum MG; Zhang HZ; Podoloff DA; Kasi LP; Curley SA; Chan JC; Roh M; Hohn DC; Brewer H
    Cancer; 1994 Feb; 73(3 Suppl):850-7. PubMed ID: 8306270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.